SAMPLE EVALUATION A retrospective Vantage read on a public company — the facts shown are drawn from public FDA, SEC, ClinicalTrials.gov, and CMS records, so you can check it yourself. This is an abbreviated teaser, not a full report on this company.
The Vantage Index · Retrospective Sample · Public Company

Sample Evaluation — HeartFlow

Retrospective · public company · facts checkable against public records. A diligence read of knowable, cited facts — not a forecast of outcomes.

VerticalDigital Health · Cardiac Imaging
TechnologySoftware as a Medical Device (SaMD)
ApplicationAI analysis of coronary CT for coronary artery disease
Public RecordNASDAQ: HTFL (listed August 2025)
Reviewed By
Arvind Ravinutala, MD  ·  Aswini Ravinutala, BME
Retrospective Sample
Numeric composite & per-domain confidence bands
in the full report
The Vantage Index TL;DR: an FDA-cleared, AI-driven cardiac-imaging SaMD with a fully traceable public record — read here against real, checkable diligence risks, not a forecast.
Chapter 1

The Vantage Index: Summary Read

A retrospective, high-level read on a public company — assembled the way a full Vantage report is: from primary public records, with factual claims cited to their sources. The numeric composite and per-domain confidence bands live in the full report; the qualitative read is below.

HeartFlow presents as an FDA-cleared Software as a Medical Device (SaMD) in the Digital Health vertical. Its technology applies AI-driven analysis to non-invasive coronary CT scans to help clinicians evaluate coronary artery disease — positioned as a non-invasive alternative to invasive testing. It is a public company listed on NASDAQ, so its regulatory footprint and capital-markets record are matters of public record. The specific clearance route, identifiers, and dates behind the FDA record are left out of this teaser.

A disciplined diligence read is not a cheerleader. Even on a company with a public, FDA-cleared footprint, the risks that genuinely exist along the way are worth naming: reimbursement and CPT/coverage dependence for a novel SaMD, the clinical-adoption curve into established cardiology workflows, and competitive pressure in cardiac imaging and analysis. Those are covered in Chapter 3 as risk considerations — qualitatively, and without invented numbers.

In the full report
  • Numeric Vantage Index composite with a credible interval
  • Per-domain scores with confidence bands across all eight domains
  • Named comparable companies and what their public records show
  • Factual claims footnoted to their public sources
Chapter 2

The Vantage Index: Domain Findings

Every full Vantage report scores eight domains. This teaser shows a high-level qualitative read per domain with one grounded, publicly checkable sentence each. Regulatory, Reimbursement, and Competitive are shown a little more fully; the rest are locked more tightly. Scores, citations, and confidence bands are in the full report.

Regulatory
Summary
HeartFlow's technology is an FDA-cleared Software as a Medical Device (SaMD) for AI-driven, non-invasive analysis of coronary CT scans — an FDA record on the public register.
Full domain analysis, the specific clearance route and its identifiers and dates, citations, and confidence band — in the full report.
Reimbursement
Summary
Coverage and CPT/coding for a novel SaMD are rarely settled at launch — reimbursement and coverage dependence is a genuine watch item for a new software modality.
Full domain analysis, CMS coverage/coding read and payer evidence base, citations, and confidence band — in the full report.
Competitive
Summary
Competitive pressure in cardiac imaging and analysis is a central watch item for a differentiated SaMD entering established diagnostic workflows.
Full domain analysis, the named competitor cohort and positioning read, citations, and confidence band — in the full report.
Clinical
Summary
The technology addresses a well-defined clinical target — evaluation of coronary artery disease — positioned as a non-invasive alternative to invasive testing.
Full domain analysis, trial-level evidence and ClinicalTrials.gov identifiers, citations, and confidence band — in the full report.
Commercial
Summary
A non-invasive alternative to invasive coronary testing addresses an established, high-volume cardiology workflow — a broad commercial surface, tempered by the adoption curve.
Full domain analysis, market and adoption record, citations, and confidence band — in the full report.
Financial
Summary
As a NASDAQ-listed public company, HeartFlow's financials are publicly filed and independently traceable through the public capital-markets record.
Full domain analysis, SEC filing-level detail and the financial trajectory, citations, and confidence band — in the full report.
IP
Locked
This teaser does not surface intellectual-property detail; the full evaluation assesses the patent estate protecting the AI-driven CT-analysis approach.
Full domain analysis, the patent family and USPTO identifiers, freedom-to-operate read, citations, and confidence band — in the full report.
Team
Locked
This teaser does not surface operating-team detail; the full report reads the operating team's public record.
Full domain analysis, operating-team assessment and prior-company track record, citations, and confidence band — in the full report.
Chapter 3

The Vantage Index: Risk Considerations

The point of a diligence read is that it flags real risks even on a strong company. These are stated qualitatively, from the knowable public picture — no invented numbers, no forecast of outcomes.

Reimbursement and coverage dependence for a novel SaMD

A novel software modality does not arrive with settled coverage and coding. Reimbursement and CPT/coverage dependence is a standard, material consideration for a Software as a Medical Device, and one a diligence read names explicitly rather than assumes away.

Clinical-adoption curve into established cardiology workflows

Fitting a new diagnostic into established cardiology practice takes time. The clinical-adoption curve into existing workflows is a genuine consideration a diligence read surfaces, independent of how adoption ultimately unfolds.

Competitive pressure in cardiac imaging and analysis

Cardiac imaging and analysis is an area other players pursue. Competitive pressure is a real consideration for any differentiated software platform addressing the same clinical problem.

In the full report
  • Each risk paired with the evidence that would change the reading, and cited comparables where the record has them
  • Reassessment triggers: the specific data points that would change the reading
  • Cross-lens stress tests — physician (MD) and biomedical engineer (BME) on each finding

See this on a company you're evaluating.

This is an abbreviated teaser, not a full report on this company. A full Vantage report includes cited sources, per-domain confidence bands and comparable companies.

Run one on a deal you're evaluating → Talk to Arvind, MD
Illustrative sample on a public company for demonstration. Vantage makes no predictive claims; this is a diligence read of knowable, cited facts, not a forecast of outcomes. HeartFlow is a public company; the facts shown here are drawn from public FDA, SEC, ClinicalTrials.gov, and CMS records and are stated at a deliberately high level in this teaser. Specific identifiers, numbers, and dates are left out of this teaser. HeartFlow is not a Vantage client, and this sample is not affiliated with or endorsed by HeartFlow.